Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, has announced it will report its third quarter financial results for 2024 on November 6th, following the close of financial markets. The company, listed on NASDAQ under the ticker RXRX, has decided not to conduct its regular earnings call for this quarter. Instead, Recursion plans to host an investor update call on November 20, 2024, after the expected completion of its proposed business combination with Exscientia plc, a public limited company based in England and Wales. The update call will be broadcasted live from Recursion's social media platforms, including X (formerly Twitter), LinkedIn, and YouTube, with opportunities for participants to ask questions. Recursion is known for leveraging machine learning algorithms and massive experimental and computational scale to industrialize drug discovery. The company is headquartered in Salt Lake City and has offices in various global locations including Toronto, Montréal, London, and the San Francisco Bay Area.

Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, has announced it will report its third quarter financial results for 2024 on November 6th, following the close of financial markets. The company, listed on NASDAQ under the ticker RXRX, has decided not to conduct its regular earnings call for this quarter. Instead, Recursion plans to host an investor update call on November 20, 2024, after the expected completion of its proposed business combination with Exscientia plc, a public limited company based in England and Wales. The update call will be broadcasted live from Recursion's social media platforms, including X (formerly Twitter), LinkedIn, and YouTube, with opportunities for participants to ask questions. Recursion is known for leveraging machine learning algorithms and massive experimental and computational scale to industrialize drug discovery. The company is headquartered in Salt Lake City and has offices in various global locations including Toronto, Montréal, London, and the San Francisco Bay Area.